Literature DB >> 10961900

Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity.

T Michigami1, N Shimizu, P J Williams, M Niewolna, S L Dallas, G R Mundy, T Yoneda.   

Abstract

Myeloma is a unique hematologic malignancy that exclusively homes in the bone marrow and induces massive osteoclastic bone destruction presumably by producing cytokines that promote the differentiation of the hematopoietic progenitors to osteoclasts (osteoclastogenesis). It is recognized that neighboring bone marrow stromal cells influence the expression of the malignant phenotype in myeloma cells. This study examined the role of the interactions between myeloma cells and neighboring stromal cells in the production of osteoclastogenic factors to elucidate the mechanism underlying extensive osteoclastic bone destruction. A murine myeloma cell line 5TGM1, which causes severe osteolysis, expresses alpha(4)beta(1)-integrin and tightly adheres to the mouse marrow stromal cell line ST2, which expresses the vascular cell adhesion molecule-1 (VCAM-1), a ligand for alpha(4)beta(1)-integrin. Co-cultures of 5TGM1 with primary bone marrow cells generated tartrate-resistant acid phosphatase-positive multinucleated bone-resorbing osteoclasts. Co-cultures of 5TGM1 with ST2 showed increased production of bone-resorbing activity and neutralizing antibodies against VCAM-1 or alpha(4)beta(1)-integrin inhibited this. The 5TGM1 cells contacting recombinant VCAM-1 produced increased osteoclastogenic and bone-resorbing activity. The activity was not blocked by the neutralizing antibody to known osteoclastogenic cytokines including interleukin (IL)-1, IL-6, tumor necrosis factor, or parathyroid hormone-related peptide. These data suggest that myeloma cells are responsible for producing osteoclastogenic activity and that establishment of direct contact with marrow stromal cells via alpha(4)beta(1)-integrin/VCAM-1 increases the production of this activity by myeloma cells. They also suggest that the presence of stromal cells may provide a microenvironment that allows exclusive colonization of myeloma cells in the bone marrow. (Blood. 2000;96:1953-1960)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10961900

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  74 in total

Review 1.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

Review 2.  Bone disease in multiple myeloma.

Authors:  Øyvind Hjertner; Therese Standal; Magne Børset; Anders Sundan; Anders Waage
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 3.  Myeloma and Bone Disease.

Authors:  Cristina Panaroni; Andrew J Yee; Noopur S Raje
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

4.  IL-19 reduces ligation-mediated neointimal hyperplasia by reducing vascular smooth muscle cell activation.

Authors:  Stephen Ellison; Khatuna Gabunia; James M Richards; Sheri E Kelemen; Ross N England; Dan Rudic; Yasu-Taka Azuma; M Alexandra Munroy; Satoru Eguchi; Michael V Autieri
Journal:  Am J Pathol       Date:  2014-05-09       Impact factor: 4.307

5.  Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.

Authors:  Yoichi Imai; Eri Ohta; Shu Takeda; Satoko Sunamura; Mariko Ishibashi; Hideto Tamura; Yan-Hua Wang; Atsuko Deguchi; Junji Tanaka; Yoshiro Maru; Toshiko Motoji
Journal:  JCI Insight       Date:  2016-04-21

Review 6.  Mechanisms of bone metastases of breast cancer.

Authors:  Larry J Suva; Robert J Griffin; Issam Makhoul
Journal:  Endocr Relat Cancer       Date:  2009-05-14       Impact factor: 5.678

7.  Serum carcinoembryonic antigen-related cell adhesion molecule 1 level in postmenopausal women: correlation with β-catenin and bone mineral density.

Authors:  C Ma; B Shuai; L Shen; Y P Yang; X J Xu; C G Li
Journal:  Osteoporos Int       Date:  2015-11-16       Impact factor: 4.507

Review 8.  Extravasation and homing mechanisms in multiple myeloma.

Authors:  Isabelle Vande Broek; Karin Vanderkerken; Benjamin Van Camp; Ivan Van Riet
Journal:  Clin Exp Metastasis       Date:  2007-10-19       Impact factor: 5.150

9.  Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells.

Authors:  Tomoko Okada; Shingo Akikusa; Hiroaki Okuno; Masato Kodaka
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

10.  Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production.

Authors:  Masahiro Abe; Kenji Hiura; Shuji Ozaki; Shinsuke Kido; Toshio Matsumoto
Journal:  J Bone Miner Metab       Date:  2008-12-05       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.